PARP1 and breast cancer: PARP inhibition is also promising for triple negative breast cancer (TNBC), which is an aggressive breast cancer characterized by high levels of replicative stress due to c-MYC amplification, EGFR activation and TP53 mutations (p53 gene was found to be mutated in approximately 80% of basal/TNBC) [135, 136].